An Emerging Leader in Cancer Diagnostics

Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics and services some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals as well as biopharma and biotech.

We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute.

Investor Highlights: Cancer Genetics Addresses the Trends in Oncology from Bench to Bedside

 Large, Global Market Opportunities

$485B GLOBAL ONOCOLOGY SPEND BY 2030

 Global Footprint Created by Highly Strategic M&A

3 TRANSFORMATIVE ACQUISITIONS IN 2014 & 2015

 Strong & Growing Partnerships with Leading BioPharma

CONTRACTS WITH 8 OF 10 TOP BIOPHARMA +650% INCREASE WITH BIOPHARMA CUSTOMERS FROM 2012 TO 2015

 Innovation Engine & Expertise Driven By Key Collaborations

18 RESEARCH COLLABOARATIONS WITH LEADING INSTITUTIONS

 Unique, Proprietary Portfolio of Genomic Tests & Panels

11 COMMERCIALLY LAUNCHED TESTS 49 US PATENTS AND 100+ FOREIGN PATENTS

 Diversified & High Growth Revenue Streams

77% Revenue Growth 2014-15 / 43% 4-YEAR CAGR<

 World-Class Management Team

100+ CUMULATIVE YEARS OF EXPERIENCE